Commenting on the financial results for 2002, Jörg Täubel Managing Director, stated:“It has been an excellent year for Richmond Pharmacology. The level of bookings for trials has continued to grow throughout our first year, and we have doubled our capacity for volunteers accordingly. We are delighted to announce that at the end of our first year of trading we exceeded all expectations in terms of studies completed and by showing profitability.“With good order books and detailed plans to accommodate more trials through the coming year, we are well positioned for another year of profitable growth for Richmond Pharmacology.”

Latest news

How Richmond Pharmacology Ensures End‑to‑End Data Integrity and Operational Continuity

March 13, 2026
Richmond Pharmacology applies a comprehensive, four‑pillar data‑security framework designed to protect participant information...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event